S

Shanghai Junshi Biosciences Co Ltd
HKEX:1877

Watchlist Manager
Shanghai Junshi Biosciences Co Ltd
HKEX:1877
Watchlist
Price: 23.1 HKD -0.6%
Market Cap: 47.6B HKD

Operating Margin
Shanghai Junshi Biosciences Co Ltd

-40.4%
Current
-132%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-40.4%
=
Operating Profit
-1B
/
Revenue
2.5B

Operating Margin Across Competitors

No Stocks Found

Shanghai Junshi Biosciences Co Ltd
Glance View

Market Cap
47.6B HKD
Industry
Biotechnology

Founded in 2012, Shanghai Junshi Biosciences Co., Ltd. emerged as a dynamic player in the biopharmaceutical industry, focusing on the discovery, development, and commercialization of innovative therapies. This company, based in Shanghai, China, has carved a niche in the highly competitive field through its robust pipeline of monoclonal antibodies, small molecule drugs, and therapeutic vaccines. Junshi Biosciences prides itself on its comprehensive R&D capabilities, operating state-of-the-art research facilities that foster significant scientific advancements. Central to its growth strategy is an ongoing commitment to addressing unmet medical needs in oncology, autoimmune, metabolic diseases, and beyond, positioning itself at the forefront of precision medicine. Junshi Biosciences generates revenue through a multifaceted business model that includes partnering with top-tier global pharmaceutical companies, engaging in strategic licensing agreements, and advancing its proprietary products through various stages of clinical trials to eventual market launch. A landmark achievement for the company was the development and commercialization of Toripalimab, China's first domestically developed anti-PD-1 monoclonal antibody approved for multiple indications, which marked a significant milestone in its financial trajectory. Such breakthroughs not only bolster its top-line revenue but also solidify its reputation as an innovator in the global biotechnology landscape. By blending scientific ingenuity with strategic collaborations, Junshi continues to expand its international footprint and deepen its impact on global health.

Shanghai Junshi Biosciences Co Ltd Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-40.4%
=
Operating Profit
-1B
/
Revenue
2.5B
What is the Operating Margin of Shanghai Junshi Biosciences Co Ltd?

Based on Shanghai Junshi Biosciences Co Ltd's most recent financial statements, the company has Operating Margin of -40.4%.

Back to Top